Attached files
Exhibit 99.1
501 Elliott Ave. W. #400 Seattle, WA 98119 |
T 206.282.7100 F 206.284.6206 |
Cell Therapeutics, Inc. Reports Outcome of
Annual Meeting of Shareholders
September 16, 2010 SeattleCell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) (the Company) announced today the results from its Annual Meeting of Shareholders (the Annual Meeting) held on Thursday, September 16, 2010.
At the Annual Meeting, shareholders elected John H. Bauer and Phillip M. Nudelman, M.D. to serve on the Companys Board of Directors until the Companys 2013 Annual Meeting. Shareholders approved the proposals to (i) amend the Companys amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock and (ii) amend the Companys 2007 Equity Incentive Plan, as amended (the Plan), to increase the number of shares available for issuance under the Plan. Shareholders ratified the selection of Stonefield Josephson, Inc. as the Companys independent auditors for the year ending December 31, 2010.
###
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk factors listed or described from time to time in the Companys filings with the U.S. Securities and Exchange Commission including, without limitation, the Companys most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
###
Media Contact:
Dan Eramian
www.CellTherapeutics.com
Page 2 of 2 | Annual Meeting Results |
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors
www.CellTherapeutics.com